Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 17
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Feirman, Shari P. Donaldson, Elisabeth Glasser, Allison M. Pearson, Jennifer L. Niaura, Ray Rose, Shyanika W. Abrams, David B. and Villanti, Andrea C. 2016. Mathematical Modeling in Tobacco Control Research: Initial Results From a Systematic Review. Nicotine & Tobacco Research, Vol. 18, Issue. 3, p. 229.

    Papadakis, Sophia Pipe, Andrew Kelly, Shannon Pritchard, Gillian Wells, George A and Papadakis, Sophia 2015. Cochrane Database of Systematic Reviews.

    Poulsen, Peter Bo Spillemose, Heidi Nielsen, Gerda Hergel, Lise-Lotte Wedell-Wedellsborg, Dorte Strand, Mette and Ringbæk, Thomas 2015. Real-life effectiveness of smoking-cessation treatments in general practice clinics in Denmark. The Escape Smoke project. Respiratory Medicine, Vol. 109, Issue. 2, p. 218.

    Herman, Patricia M. Szczurko, Orest Cooley, Kieran and Seely, Dugald 2014. A Naturopathic Approach to the Prevention of Cardiovascular Disease. Journal of Occupational and Environmental Medicine, Vol. 56, Issue. 2, p. 171.

    Ruger, Jennifer Prah and Lazar, Christina M. 2012. Economic Evaluation of Pharmaco- and Behavioral Therapies for Smoking Cessation: A Critical and Systematic Review of Empirical Research. Annual Review of Public Health, Vol. 33, Issue. 1, p. 279.

    Corrao, Giovanni Scotti, Lorenza Zambon, Antonella Baio, Gianluca Nicotra, Federica Conti, Valentino Capri, Stefano Tragni, Elena Merlino, Luca Catapano, Alberico L. and Mancia, Giuseppe 2011. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. Atherosclerosis, Vol. 217, Issue. 2, p. 479.

    Ito, Marcia K. Nanchen, David Rodondi, Nicolas Paccaud, Fred Waeber, Gérard Vollenweider, Peter and Marques-Vidal, Pedro 2011. Statins for Cardiovascular Prevention According to Different Strategies. American Journal Cardiovascular Drugs, Vol. 11, Issue. 1, p. 33.

    Sanchez, Daniel R. Diez Roux, Ana V. Michos, Erin D. Blumenthal, Roger S. Schreiner, Pamela J. Burke, Gregory L. and Watson, Karol 2011. Comparison of the Racial/Ethnic Prevalence of Regular Aspirin Use for the Primary Prevention of Coronary Heart Disease from the Multi-Ethnic Study of Atherosclerosis. The American Journal of Cardiology, Vol. 107, Issue. 1, p. 41.

    Sherif, Mohammad A. Nienaber, Christoph A. Toelg, Ralph Abdel-Wahab, Mohamed Geist, Volker Schneider, Steffen Senges, Jochen Kuck, Karl-Heinz Tebbe, Ulrich and Richardt, Gert 2011. Impact of smoking on the outcome of patients treated with drug-eluting stents: 1-year results from the prospective multicentre German Drug-Eluting Stent Registry (DES.DE). Clinical Research in Cardiology, Vol. 100, Issue. 5, p. 413.

    Annemans, Lieven Wittrup-Jensen, Kim and Bueno, Héctor 2010. A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention. Journal of Medical Economics, Vol. 13, Issue. 3, p. 418.

    Linden, Kari Jormanainen, Vesa Linna, Miika Sintonen, Harri Wilson, Koo and Kotomäki, Teija 2010. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Current Medical Research and Opinion, Vol. 26, Issue. 3, p. 549.

    Poulsen, Peter Bo Dollerup, Jens and Møller, Ann Merete 2010. Is a percentage a percentage? Systematic review of the effectiveness of Scandinavian behavioural modification smoking cessation programmes. The Clinical Respiratory Journal, Vol. 4, Issue. 1, p. 3.

    Booth, F. W. and Laye, M. J. 2009. Lack of adequate appreciation of physical exercise's complexities can pre-empt appropriate design and interpretation in scientific discovery. The Journal of Physiology, Vol. 587, Issue. 23, p. 5527.

    Erhardt, Leif 2009. Cigarette smoking: An undertreated risk factor for cardiovascular disease. Atherosclerosis, Vol. 205, Issue. 1, p. 23.

    Grayland, J. and Wilson, R. 2009. Improving male life expectancy in Birmingham. Public Health, Vol. 123, Issue. 1, p. e50.

    Sorensen, Sonja V. Frick, Kevin D. Wade, Alexander Simko, Robert and Burge, Russel 2009. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Clinical Therapeutics, Vol. 31, Issue. 4, p. 862.

    Anthenelli, Robert M 2007. A call to action: new treatment options provide even more reasons to intervene in tobacco dependence. Nature Clinical Practice Cardiovascular Medicine, Vol. 4, Issue. 9, p. 462.

  • International Journal of Technology Assessment in Health Care, Volume 23, Issue 1
  • January 2007, pp. 71-79

Primary prevention of cardiovascular disease: Cost-effectiveness comparison

  • Oscar H. Franco (a1), Arno J. der Kinderen (a2), Chris De Laet (a3), Anna Peeters (a4) and Luc Bonneux (a5)
  • DOI:
  • Published online: 01 January 2007

Objectives: The aim of this study was to evaluate the cost-effectiveness of four risk-lowering interventions (smoking cessation, antihypertensives, aspirin, and statins) in primary prevention of cardiovascular disease.

Methods: Using data from the Framingham Heart Study and the Framingham Offspring study, we built life tables to model the benefits of the selected interventions. Participants were classified by age and level of risk of coronary heart disease. The effects of risk reduction are obtained as numbers of death averted and life-years saved within a 10-year period. Estimates of risk reduction by the interventions were obtained from meta-analyses and costs from Dutch sources.

Results: The most cost-effective is smoking cessation therapy, representing savings in all situations. Aspirin is the second most cost-effective (€2,263 to €16,949 per year of life saved) followed by antihypertensives. Statins are the least cost-effective (€73,971 to €190,276 per year of life saved).

Conclusions: A cost-effective strategy should offer smoking cessation for smokers and aspirin for moderate and high levels of risk among men 45 years of age and older. Statin therapy is the most expensive option in primary prevention at levels of 10-year coronary heart disease risk below 30 percent and should not constitute the first choice of treatment in these populations.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *